A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Latest Information Update: 17 May 2024
At a glance
- Drugs Alpelisib (Primary) ; Tipifarnib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker
- Acronyms KURRENT; KURRENT-HN
- Sponsors Kura Oncology
- 02 May 2024 According to a Kura Oncology media release, the company plans to present data from this trial in the first half of 2025.
- 27 Feb 2024 According to a Kura Oncology media release, company continues to evaluate tipifarnib in combination with alpelisib in patients with PIK3CA-dependent HNSCC as part of its ongoing KURRENT-HN dose-escalation trial. Complete enrollment of two expansion cohorts to support determination of the optimal biologically active dose for tipifarnib in combination with alpelisib by the end of 2024.
- 03 Aug 2023 According to a Kura Oncology media release, the company expects to initiate dose expansion in the KURRENT-HN trial of tipifarnib and alpelisib in mid-2024.